A phase I clinical trial of bavituximab and paclitaxel in patients with HER2 negative metastatic breast cancer

Bavituximab is a chimeric monoclonal antibody that targets phosphatidylserine (PS). PS is externalized on cells in the tumor microenvironment when exposed to hypoxia and/or other physiological stressors. On attaching to PS, bavituximab is thought to promote antitumor immunity through its effects on...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalasani, Pavani, Marron, Marilyn, Roe, Denise, Clarke, Kathryn, Iannone, Maria, Livingston, Robert B, Shan, Joseph S, Stopeck, Alison T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529343/
https://www.ncbi.nlm.nih.gov/pubmed/25826750
http://dx.doi.org/10.1002/cam4.447

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529343/
https://www.ncbi.nlm.nih.gov/pubmed/25826750
http://dx.doi.org/10.1002/cam4.447

Ejemplares similares